Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Mechanistic Study to Evaluate the Effect of HTD1801 in Delaying the Progression of Renal Impairment in Patients With Type 2 Diabetes and Chronic Kidney Disease.

NCT07496177 is registered in ClinicalTrials.gov with Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT07496177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07496177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Mechanistic Study to Evaluate the Effect of HTD1801 in Delaying the Progression of Renal Impairment in Patients With Type 2 Diabetes and Chronic Kidney Disease.
Lead sponsor
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Recruiting
Start date
July 9, 2026
Completion date
June 30, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ckd, t2dm